ORAMED PHARMACEUTICALS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2022-12-31 was $20.00K, a 96.78% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $42.00K, a 99.62% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-11-30 was $622.00K.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $11.08M.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2022 was $62.00K.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2021 was $21.41M, a 164584.62% increase from fiscal 2020.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2020 was $13.00K.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2015 was $8.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2022-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $62.00K 10-K · filed 2024-03-06 |
| 2022-09-30 | $42.00K 10-Q · filed 2023-11-09 | |
| 2021-11-30 | $622.00K 10-Q · filed 2022-01-11 | |
| 2021-09-30 | $11.08M 10-Q · filed 2022-11-10 | |
| 2021-08-31 | $14.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $21.41M 10-K · filed 2023-03-06 |
| 2021-06-30 | $3.69M 10-Q · filed 2022-08-10 | |
| 2021-05-31 | $2.99M 10-Q · filed 2021-07-14 | |
| 2021-03-31 | $6.72M 10-Q · filed 2022-05-12 | |
| 2021-02-28 | $3.75M 10-Q · filed 2021-04-13 | |
| 2020-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $13.00K 10-K · filed 2021-11-24 |
| 2020-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-14 | |
| 2017-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-07-06 | |
| 2017-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-04-05 | |
| 2016-11-30 | $320.00K 10-Q · filed 2017-01-11 | |
| 2015-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-11-29 | $8.00K 10-K · filed 2017-11-29 |
| 2015-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-07-01 | |
| 2013-08-31 | $109.58K 10-Q · filed 2014-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |